Recent work has provided new insights into how altered B cell-intrinsic signals—through the
B cell receptor (BCR) and key co-receptors—function together to promote the pathogenesis …

The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-
inducing ligand), are critical factors in the maintenance of the B cell pool and humoral …

Highlights•TACI promotes TI antibody responses and controls autoimmunity and
lymphoproliferation.•TACI integrates signals from multiple pathways in B-cells to regulate …

BAFF is a critical cytokine supporting the survival of mature naïve B cells, acting through the
BAFFR receptor. Recent studies show that BAFF and BAFFR are also required for the …

Purpose and methods B cell-activating factor (BAFF) contributes to the pathogenesis of
autoimmune diseases including systemic lupus erythematosus (SLE). Although several anti …

The B cell activating factor (BAFF) inhibitor, belimumab, is the first biologic drug approved for
the treatment of SLE, and exhibits modest, but durable, efficacy in decreasing disease flares …

Abstract Purpose of the Review Systemic lupus erythematosus (SLE) is driven by nucleic
acid-containing antigens that stimulate endosomal TLRs. We review new advances in our …

Perfluorooctanoic acid (PFOA) has been identified as a new persistent organic pollutant.
This pollutant is ubiquitous in water and environments. Although PFOA is toxic to fishes, the …

In 1957, Holborow and colleagues 1 identified antibodies targeting cell nuclei in lupus sera,
thereby linking B cells to the pathogenesis of human systemic lupus erythematosus (SLE). In …

Belimumab has therapeutic benefit in active systemic lupus erythematosus (SLE), especially
in patients with high-titer anti-dsDNA antibodies. We asked whether the profound B cell loss …